The expression of KLF5 has been shown to decrease in TAC mice treated with ICG001, a specific inhibitor of the Wnt/β-catenin signaling pathway that inhibits β-catenin/cyclic AMP response element-binding (CREB) protein transcription, resulting in the reduction of fibrosis [9]. Here, KLF5 is linked to persistent truncus arteriosus.